Is a DEA (Drug Enforcement Administration) registration required to prescribe pregabalin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

DEA Registration for Pregabalin Prescribing

Yes, you need a DEA registration to prescribe pregabalin because it is classified as a Schedule V controlled substance in the United States. 1

Controlled Substance Classification

Pregabalin has been designated as a Schedule V controlled substance by the Drug Enforcement Administration (DEA) due to its potential for abuse and dependence. 2 This is the lowest schedule of controlled substances, indicating the lowest potential for abuse among controlled medications, but it still requires DEA registration to prescribe legally. 2

Why Pregabalin is Controlled

The controlled substance designation stems from documented abuse potential:

  • Abuse patterns have been documented in patients with prior drug-seeking behavior, with cases reporting consumption of up to 88,500 mg over 28 days (far exceeding therapeutic dosing). 3

  • High-dose use above recommended ranges occurs in approximately 9.6% of users (≥600 mg/day for 6 months), with male gender and concurrent prescription of antipsychotics and benzodiazepines associated with increased risk of supra-therapeutic dosing. 4

  • Euphoric effects have been reported at doses exceeding therapeutic ranges, particularly in individuals with substance use history. 3

Practical Prescribing Requirements

To legally prescribe pregabalin, you must:

  • Hold an active DEA registration in the state where you practice
  • Include your DEA number on all pregabalin prescriptions
  • Follow state-specific controlled substance prescribing regulations, which may include prescription monitoring program (PMP) checks

Common pitfall: Some clinicians mistakenly believe Schedule V substances don't require DEA registration because they have lower abuse potential than Schedule II-IV drugs—this is incorrect. All controlled substances from Schedule II through V require valid DEA registration for prescribing. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pregabalin: an antiepileptic agent useful for neuropathic pain.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007

Research

Potential for pregabalin abuse or diversion after past drug-seeking behavior.

The Journal of the American Osteopathic Association, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.